louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00977639: Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies
Official title: Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neoplasm Metastasis
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2009-09-16
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of malignancy

Brief summary: The pathworks tissue of origin test is a microarray-based test with the goal of identifying the tissue of origin in patients with metastatic tumors of unknown primary site.


Eligibility criteria: Inclusion Criteria:1 Subjects must be at least 18 years old. The TOO test is designed to determine the tissue of origin of common adult malignancies. There are no gender/ethnic restrictions.

2 Patients with a diagnosis of malignancy established by pathologic review of H\&E staining of tumor biopsy or tumor resection without definitive determination of tissue of origin as assessed by the PI. Samples must have been obtained within three months of enrollment, or the patient must still be under active evaluation for tissue of origin at the time of enrollment. There are no limitations on prior therapy and time from last prior therapy.

3 Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:1 Patients under the age of 18 are excluded. There are no exclusions based on gender/ethnicity.

2 There are no exclusion requirements due to co-morbid disease or incurrent illness, as needed.

3 Pregnancy or nursing participants will not be excluded from the study.

4 Patients with a diagnosis of leukemia including acute myelogenous leukemia, acute lymphocytic leukemia, hairy cell leukemia, chronic myelogenous leukemia and chronic lymphocytic leukemia are excluded from enrollment on this study. The TOO test does not cover these diagnoses.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: James L Zehnder
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05257239: Acceptability and User Perceptions of Artificial Intelligence-based Mobile Applications Adoption for Weight Management: A Sequential Explanatory Study
Official title: Acceptability and User Perceptions of Artificial Intelligence-based Mobile Applications
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Weight Management
Lead sponsor: National University Health System, Singapore
Sponsor class: OTHER
First posted: 2022-02-25
Enrollment: 600
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Singaporean population

Brief summary: To understand the user perceptions of AI and non-AI-based mobile apps for weight management in people with overweight and obesity.


Eligibility criteria: Inclusion Criteria:

* Participants will be recruited if they are above 21 years old, have a BMI ≥23kg/m2 and understand English language.

Exclusion Criteria:

* There will be no exclusion criteria to maximize representation of the general population of Singaporean who are overweight and obese.

Primary outcomes:
measure: Unified Theory of Acceptance and Use of Technology 2 (UTAUT2)
timeFrame: 2021-2023
Secondary outcomes:
measure: Qualitative interviews
timeFrame: 2021-2023
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National University of Singapore
Study officials:
References:
Clinical trial NCT03900039: An Assessment of 4 Different Bearing Types in Hip Replacement Types to Analsye the Lowest Wear Rates of Polyethylene
Official title: Randomized Control Trial of Four Bearing Surfaces in Primary Total Hip Arthroplasty in Patients Over the Age of 18 Years
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arthroplasty Complications
Hip Arthritis
Keywords: Hip arthroplasty
Tribology
wear
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2019-04-02
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of the study is to assess the ideal bearing surfaces in hip replacement by comparing 4 different combinations. In a hip replacement this means what the head and the socket liner are made of.

Detailed description: In hip replacements, arguably the most important thing for survivorship is what rubs against what.

Traditionally surgeons used metal (Cobalt-Chrome) against a conventional polyethylene (plastic). More recently (around 15 years ago) a newer more dense type of polyethylene (called XLPE) had been developed and a new type of head called Oxidized Zirconium was also developed.

In this trial, adults who were undergoing hip replacements were randomized assigned into one of the four groups:

Group 1: old plastic vs metal head Group 2: Old plastic against Oxidized Zirconium Group 3: New plastic versus metal head Group 4 New plastic vs Oxidized Zirconium

All patients were followed up for a minimum of 10 years to assess which group wore the most amount of polyethylene and which group had the best survival rate.

Eligibility criteria: Inclusion Criteria:

* All adults with no history of cancer, infection of the hip and with the capacity to make informed consent for the trial

Exclusion Criteria:

* those under the age of 18 and over 65. Those with a history of cancer and infection. Those without the capacity to make an informed consent.

Primary outcomes:
measure: Wear rates of polyethylene over 10 years
timeFrame: Over 10 years of wear rates
Secondary outcomes:
measure: Survivorship of implant combinations
timeFrame: over 10 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
References:
citation: Atrey A, Ward SE, Khoshbin A, Hussain N, Bogoch E, Schemitsch EH, Waddell JP. Ten-year follow-up study of three alternative bearing surfaces used in total hip arthroplasty in young patients: a prospective randomised controlled trial. Bone Joint J. 2017 Dec;99-B(12):1590-1595. doi: 10.1302/0301-620X.99B12.BJJ-2017-0353.R1.
citation: Rames RD, Stambough JB, Pashos GE, Maloney WJ, Martell JM, Clohisy JC. Fifteen-Year Results of Total Hip Arthroplasty With Cobalt-Chromium Femoral Heads on Highly Cross-Linked Polyethylene in Patients 50 Years and Less. J Arthroplasty. 2019 Jun;34(6):1143-1149. doi: 10.1016/j.arth.2019.01.071. Epub 2019 Feb 5.
Clinical trial NCT06679439: Comparison of Dermis Vs. Auricular Cartilage Grafts for the Surgical Correction of Lower Eyelid Retraction
Official title: A Prospective, Randomized Comparison of Dermis Vs. Auricular Cartilage Grafts for the Surgical Correction of Lower Eyelid Retraction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lower Eyelid Retraction
Keywords: eyelid
lower eyelid retraction
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
Collaborators: name: Coordination for the Improvement of Higher Education Personnel
First posted: 2024-11-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to compare the effectiveness of two autologous grafts-dermis and auricular cartilage-in the surgical correction of the lower eyelid retraction. Our primary focus was assessing changes in lower eyelid position using lower eyelid Margin to corneal Reflex Distance measurements, a.k.a Margin reflex distance 2 (MRD2).

Detailed description: This prospective, randomized interventional study includes patients with stable LER. Patients are randomly assigned to undergo surgical correction using either auricular cartilage or dermis grafts, with the vertical dimension configured to be twice the scleral show height. MRD2 measurements were taken pre-operatively and at several post-operative intervals, with complications and outcomes recorded.

Eligibility criteria: Inclusion Criteria:

* eyelid retraction, scleral show

Exclusion Criteria:

* incomplete follow-up (less than 6 months), pregnancy and other abnormal ocular conditions or symptoms that preclude the patient's admission to the study, according to the clinical judgment of the investigator.

Primary outcomes:
measure: Lower eyelid Margin Reflex Distance measurements (MRD2) in millimeters
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: University of Sao Paulo General Hospital
state: SP
Study officials:
References:
Clinical trial NCT00802139: Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin
Official title: A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Iron Deficiency Anemia
Keywords: iron deficiency anemia
pregnant women with iron deficiency anemia
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2008-12-04
Enrollment: 58
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: multi-center, prospective, randomized, open-labeled, active-drug-controlled, two-parallel-group-comparison(venoferrun group vs Bolgre group)study


Eligibility criteria: Inclusion Criteria:

* 30\~32nd weeks pregnant women aged over 18 years
* Women who have Hb level of more than 10.0g/dL a week before study initiation
* Patients who agree to participate in this study in writing

Exclusion Criteria:

* Patients who have participated in another clinical study in recent 3 months
* Patients who are prone to acute hemorrhage during pregnancy
* Patients who have shown intolerance to iron therapy
* Hemolytic anemia, hemoglobinopathies (thalassemia, sickle cell)
* Bleeding tendency, hypersplenism
* Chronic heart failure, Class II-IV heart disease, uncontrolled arterial hypertension (DBP ≥ 115mmHg), deep vein thrombosis, thrombocytosis, chronic renal disease
* Severe renal failure patients (2.5 times or more higher plasma creatinine level than high limit of normal state)
* Patients with severe liver dysfunction (2.5 times or more higher AST or ALT than high limit of normal state)
* Patients with doubled or more CK level than high limit of normal state
* Patients who are regarded as ineligible for this study by investigator

Primary outcomes:
measure: Change of plasma hemoglobin level
timeFrame: 5 week
Secondary outcomes:
measure: Target Hb achievement rate(11g/dL), Transferrin saturation(%), Ferritin(ng/mL), TIBC(ug/dL), MCV(fl), MCH(pg) and change in reticulocyte counts
timeFrame: 5 week
Other outcomes:
Locations:
city: KwangJu
country: Korea, Republic of
facility: Chonnam National Universitiy Hospital
city: Seoul
country: Korea, Republic of
facility: Asan Hospital
city: Seoul
country: Korea, Republic of
facility: Catholic University of Korea Kangnam St. Mary's Hospital
Study officials:
affiliation: Asan hospital OB/Gyn unit
name: Kim AM, ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02002039: Neuroprotective Role of Erythropoietin in Perinatal Asphyxia
Official title: Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Perinatal Asphyxia
Keywords: Perinatal asphyxia
erythropoietin
Lead sponsor: Sheri Kashmir Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2013-12-05
Enrollment: 100
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Whether Erythropoietin improves the neurological outcomes of neonates with perinatal asphyxia.

Detailed description: will be a randomized trial

Eligibility criteria: Inclusion Criteria:

* Babies with severe perinatal asphyxia with moderate to severe HIE in the immediate neonatal period

Exclusion Criteria:

* Babies with congenital malformations
* Small for gestational age babies
* Babies with chromosomal anomalies

Primary outcomes:
measure: Death or moderate or severe disability at 18-22 months of age
timeFrame: 18-22 months
Secondary outcomes:
measure: Disability
timeFrame: 18-22 months
measure: Bayley psychomotor development index
timeFrame: 18-22 months months
measure: Hearing loss at 18-22 months
timeFrame: 18-22 months
Other outcomes:
Locations:
city: Srinagar
country: India
facility: Sheri-Kashmir Institute of Medical Sciences
state: Jammu and kashmir
Study officials:
affiliation: SKIMS
name: Feroz Shaheen, MD
role: STUDY_CHAIR
affiliation: SKIMS
name: Prof. WAjid Ali
role: STUDY_DIRECTOR
References:
Clinical trial NCT01439139: Bone UltraSonic Scanner (BUSS): Validation Study
Official title: Portable Bone Ultrasonometer for Osteoporosis Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoporosis
Osteopenia
Keywords: Osteoporosis
ultrasound
sonometer
DXA
Lead sponsor: Artann Laboratories
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Aging (NIA)
First posted: 2011-09-23
Enrollment: 130
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Postmenopausal women

Brief summary: The aim of clinical study is to assess effectiveness of Bone UltraSonic Scanner (BUSS) versus densitometry (DXA) in osteoporosis detection.

Detailed description: Study will conduct measurements in a group of postmenopausal women and use their DXA examination data as a control. BUSS data will be able to discriminate between postmenopausal women with osteoporosis compared with no osteoporosis defined by DXA measurements.

Eligibility criteria: Inclusion Criteria:

* Postmenopausal
* Age 50-90 years
* Any race or ethnicity
* DXA spine and hip exam within one year

Exclusion Criteria:

* Open wounds or rashes on the testing area
* Active skin infection
* Recent tibia surgery
* Abnormal tibia anatomy
* Body Mass Index \> 34.9 kg/m2
* Current or previous tibial fracture on side of testing
* Stroke or with total or partial paralysis with residual disability lasting more than 3 months

Current or recent (within past 6 months) use of bone-active drugs:

* Bisphosphonates
* Calcitonin
* Estrogens or selective estrogen receptor modulator (SERM)
* Therapeutic doses of fluoride (\> 2mg/day)
* Teriparatide used currently or within past 3 months
* Drugs under research protocols, and
* Unstudied or unapproved drugs
* Presence of metabolic bone disease

Primary outcomes:
measure: BUSS data will be able to discriminate between postmenopausal women with osteoporosis compared with no osteoporosis defined by DXA measurements.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: Catholic Health System Affiliates & Sister's of Charity Hospital
state: New York
Study officials:
affiliation: Artann Laboratories, Inc
name: Armen Sarvazyan, Ph.D., D.Sc.
role: STUDY_CHAIR
References:
Clinical trial NCT00217139: A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
Official title: A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hepatitis C, Chronic
Keywords: Hepatitis C
Celgosivir
HCV
Genotype 1
Non-responders
Early Viral Response
EVR
Lead sponsor: BioWest Therapeutics Inc
Sponsor class: INDUSTRY
First posted: 2005-09-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.


Eligibility criteria: Inclusion Criteria:

* 18-65 years of age, inclusive
* primary diagnosis of chronic HCV infection
* non-responders to previous pegylated interferon-based therapy

Exclusion Criteria:

* patients naive to interferon-based therapy for chronic HCV infection

Primary outcomes:
measure: Safety analysis
measure: HCV viral load
Secondary outcomes:
Other outcomes:
Locations:
city: Calgary
country: Canada
state: Alberta
city: Edmonton
country: Canada
state: Alberta
city: Vancouver
country: Canada
state: British Columbia
city: Winnipeg
country: Canada
state: Manitoba
city: Halifax
country: Canada
state: Nova Scotia
city: London
country: Canada
state: Ontario
Study officials:
affiliation: BioWest Therapeutics Inc
name: Jim Pankovich
role: STUDY_DIRECTOR
References:
Clinical trial NCT00396539: Hydrogen Sulfide Production by Oral Microflora
Official title: Detection of Hydrogen Sulfide Production by Oral Microflora Samples
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Oral Malodor (Halitosis)
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2006-11-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: Oral malodor is a common condition. In most cases this condition results from the proteolytic activity of anaerobic oral bacteria. These bacteria produce volatile sulfide compounds which are fowl smelling and are felt during exhalation and speech. the aim of the present study is to examine a simple method of detecting these bacteria in samples taken from the oral cavity of oral malodor patients.


Eligibility criteria: Inclusion Criteria:

* oral malodor patients

Exclusion Criteria:

* smokers, users of antibiotic one month prior to study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Nir Sterer, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00378339: Gold Against Pains From Osteoarthrosis in the Knee
Official title: Clinical Effects From Implants of Gold Around the Arthrotic Knee Joint. A Randomized, Double Blind, Placebo Controlled Investigation.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Arthritis
Keywords: arthrosis
gold
Lead sponsor: Northern Orthopaedic Division, Denmark
Sponsor class: OTHER
Collaborators: name: University of Aarhus
name: Aarhus University Hospital
First posted: 2006-09-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Gold implantation around arthritic joints is a very popular treatment - but the effect has never been controlled.

Detailed description: Randomization between

1. Gold (4 x 3 berlocks, injected under local anesthesia) and
2. Sham operation - only local anesthesia Functional and pain measures reported through the next 6 months.

Eligibility criteria: Inclusion Criteria:

Arthrosis in knee joint

Exclusion Criteria:

Need for NSAID

Primary outcomes:
measure: VAS
Secondary outcomes:
measure: WOMAC
Other outcomes:
Locations:
city: Frederikshavn
country: Denmark
facility: Northern Orthopaedic Division, Klinik Frederikshavn
state: Northern Jutland
Study officials:
affiliation: Northern Orthopaedic Division
name: Mogens B Laursen, MD, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03402139: Early Childhood Obesity Programming by Intrauterine Growth Restriction
Official title: Molecular Basis of Early Childhood Obesity Programming by Intrauterine Growth Restriction
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Childhood Obesity
Epigenetics
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
First posted: 2018-01-18
Enrollment: 400
Sex: ALL
Minimum age (years): 1
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Term AGA and IUGR singleton infants

Brief summary: The molecular mechanisms underlying developmental programming of childhood obesity remain poorly understood. Here, the investigators address major questions about early childhood obesity programming by studying CD3+ T-cells from intrauterine growth restricted (IUGR) newborns who have an increased risk for obesity and other metabolic disorders in adult life.

Detailed description: Epidemiological studies of multiple cohorts suggest an increased risk for obesity, cardiovascular disease-related death and type 2 diabetes in low birth weight infants. However, the molecular mechanisms underlying developmental programming of childhood obesity remain poorly understood. Alterations in DNA methylation during fetal life have been proposed to be one of the mechanisms that regulate this phenotype. Here, the investigators address major questions about early childhood obesity programming by studying purified subpopulations of CD3+ T-cells from intrauterine growth restricted (IUGR) newborns who have an increased risk for obesity and other metabolic disorders in adult life. The investigators will correlate altered CD3+ T-cell DNA methylation profiles in cord and peripheral blood samples and functional changes in CD3+ T-cells with adiposity in childhood.

Eligibility criteria: Inclusion Criteria:

* Healthy singleton term IUGR and AGA infants whose mothers are followed by the Obstetric Department of Montefiore Medical Center and who deliver at the Weiler Division of Montefiore Medical Center.

Exclusion Criteria:

* Multiple gestation, maternal depression, maternal renal disease, infants in extremis, Apgar score \<7 at 5 min and umbilical artery pH ≤7.25, chromosomal/ congenital abnormalities, congenital infections and inborn errors of metabolism. We will also exclude infants born to mothers with a history of maternal smoking in the 2nd and 3rd trimester of pregnancy and maternal gestational diabetes/T2D.

Primary outcomes:
measure: Growth velocity
timeFrame: Until 24 months of age
measure: DNA methylation of CD3+ T-cells
timeFrame: At birth and 24 months of age
measure: T-cell function
timeFrame: At birth, 12 and 24 months of age
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Jack D. Weiler Hospital
state: New York
Study officials:
affiliation: Montefiore Medical Center/Albert Einstein College of Medicine
name: Mamta Fuloria, MD
role: PRINCIPAL_INVESTIGATOR
References: